Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Foghorn Therapeutics ( (FHTX) ).
On April 21, 2026, Foghorn Therapeutics announced preclinical data for several oncology programs presented at the 2026 American Association for Cancer Research Annual Meeting, including its selective SMARCA2 inhibitor FHD-909 and selective CBP, EP300 and ARID1B degrader candidates. The data underscore the company’s strategy of exploiting chromatin biology and synthetic lethal relationships in genetically defined cancers, reinforcing its positioning as a leader in targeting chromatin regulators and supporting the value of its Lilly partnership and broader precision-oncology pipeline.
The company also furnished an updated April 2026 investor presentation outlining a broad pipeline of first-in-class precision therapeutics, multi-billion-dollar market opportunities and its progress in advancing FHD-909 through a Phase 1 trial while moving additional degrader programs toward IND-enabling studies. With substantial non-dilutive funding from Lilly and a strengthened balance sheet after a January 2026 financing, Foghorn appears well-capitalized to progress its chromatin-focused drugs, a development that is significant for investors watching emerging approaches to “undruggable” cancer targets.
The most recent analyst rating on (FHTX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include constructive corporate updates—added financing and extended runway plus clinical progress and leadership strengthening—while valuation offers limited support due to a negative P/E and no dividend.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on precision oncology, using its Gene Traffic Control Platform to target chromatin biology and previously undruggable epigenetic regulators. Its pipeline includes enzyme inhibitors and protein degraders such as the SMARCA2 inhibitor FHD-909 and selective CBP, EP300 and ARID1B degraders, addressing genetically defined cancers including SMARCA4- and ARID1A-mutant tumors.
The company has a major strategic collaboration with Eli Lilly, which includes a 50/50 U.S. economic split on two lead programs and tiered ex-U.S. royalties, and received $380 million in upfront consideration from that deal. As of December 31, 2025, Foghorn reported $158.9 million in cash and equivalents, supplemented by $50 million raised in January 2026, providing a cash runway into the first half of 2028 and supporting advancement of multiple oncology programs.
Average Trading Volume: 162,484
Technical Sentiment Signal: Hold
Current Market Cap: $285.9M
For a thorough assessment of FHTX stock, go to TipRanks’ Stock Analysis page.